Skip to main content
HCPCS J2353 · Level II · Part B drug

HCPCS J2353: Injection, octreotide, depot form for intramuscular injection, 1 mg

Reviewed by QuickIntell RCM Editorial Team · Last reviewed

Data effective
Data currency: ASP payment limits October 2026 (effective October 1, 2026); MUE and NCCI edits 2026 Q4 (effective October 1, 2026); OPPS Addendum B July 2026 (effective July 1, 2026). Next CMS release: January 1, 2027 (ASP, MUE, NCCI and OPPS quarterly updates).

Key facts for J2353

Billing unit
1 MG
Octreotide injection, depot
ASP payment limit
$211.321
October 2026; +1.6% vs July 2026
Practitioner MUE
60
MAI 3
OPPS status
SI K
APC 1207
NCCI exposure
no PTP pairs
Coverage articles
1
7 states

TL;DR

HCPCS J2353 is the Level II code for Injection, octreotide, depot form for intramuscular injection, 1 mg, billed per 1 MG. The Medicare Part B ASP payment limit for October 2026 is $211.321 per billing unit, up 1.6% from July 2026. The practitioner MUE allows up to 60 units per date of service (MAI 3). Under OPPS it carries status indicator K in APC 1207. With a 1 mg billing unit, a single administration can be hundreds of units; the unit count on the claim must equal the milligrams given, and rounding rules for partial units follow the contractor's guidance. The ASP crosswalk maps 9 NDCs to it, sold as Sandostatin Lar Depot, Octreotide Acetate by Novartis Pharmaceuticals Corporation, Teva Pharmaceuticals USA, Inc., Mylan Institutional LLC. 1 Medicare coverage article lists the code across 7 states, including .

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J2353 at $211.321 per 1 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $208.095 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J2353
QuarterPayment limitPerCoinsurance
October 2026$211.3211 MG20%
July 2026$208.0951 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 9 NDCs from 3 labelers to J2353. Report the NDC in the claim's drug segment and bill the number of J2353 units that equals the quantity administered divided by 1 MG; the last column gives units per full package.

NDCs that crosswalk to J2353
NDCDrug nameLabelerPackage sizeBilling units / package
00078-0811-81Sandostatin Lar DepotNovartis Pharmaceuticals Corporation1 × 110
00078-0818-81Sandostatin Lar DepotNovartis Pharmaceuticals Corporation1 × 120
00078-0825-81Sandostatin Lar DepotNovartis Pharmaceuticals Corporation1 × 130
00480-9257-08Octreotide AcetateTeva Pharmaceuticals USA, Inc.1 × 110
00480-9259-08Octreotide AcetateTeva Pharmaceuticals USA, Inc.1 × 120
00480-9262-08Octreotide AcetateTeva Pharmaceuticals USA, Inc.1 × 130
67457-0756-10Octreotide AcetateMylan Institutional LLC1 × 110
67457-0759-20Octreotide AcetateMylan Institutional LLC1 × 120
67457-0762-30Octreotide AcetateMylan Institutional LLC1 × 130

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for J2353. For practitioners the limit is 60 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J2353 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services603 Date of Service Edit: ClinicalClinical: Society Comment
Facility outpatient hospital603 Date of Service Edit: ClinicalClinical: Society Comment
DME supplier03 Date of Service Edit: ClinicalCMS Policy

NCCI edits and add-on relationships

No active practitioner PTP pair lists J2353 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

J2353 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

1 current Medicare Administrative Contractor article lists J2353 in their HCPCS tables, covering 7 states. Each article carries the covered and non-covered ICD-10 codes that medical-necessity denials (CARC 50) are adjudicated against.

Billing and Coding Articles listing J2353
ArticleTitleContractor(s)StatesRelated LCD
Billing and Coding: Octreotide Acetate for Injectable Suspension (Sandostatin® LAR Depot)Palmetto GBAAL GA NC SC TN VA WVL33438

Hospital outpatient (OPPS) status

In the July 2026 OPPS Addendum B, J2353 carries status indicator K and is assigned to APC 1207, with a published national unadjusted payment of $208.10. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Common denials for J2353 and how to prevent them

CARC 16 · M119

NDC missing, invalid or not matched to the HCPCS code

CARC 151 · N362

units billed exceed the MUE for the date of service

CARC 50 · N115

diagnosis not covered by the applicable coverage article or LCD

How QuickIntell checks J2353 before the claim leaves

QuickCode validates the NDC-to-unit conversion against the current ASP crosswalk, checks units against every published MUE setting and flags PTP and add-on conflicts on the same claim. QuickRCM routes CARC 16, 151 and 50 denials on drug lines with the matching coverage article attached so the appeal starts with evidence.

Explore QuickCodeExplore QuickRCMBook a demo

Frequently asked questions — HCPCS J2353

What does HCPCS code J2353 describe?

J2353 is defined by CMS as "Injection, octreotide, depot form for intramuscular injection, 1 mg". Each billing unit represents 1 MG, so the units reported on the claim must equal the dose administered divided by that unit.

What is the Medicare reimbursement for J2353 in October 2026?

The ASP-based payment limit is $211.321 per 1 MG, with 20% beneficiary coinsurance. Medicare Administrative Contractors apply this limit; commercial payers use their own fee schedules. The July 2026 limit was $208.095.

How many units of J2353 can be billed per day?

The practitioner Medically Unlikely Edit is 60 units per date of service with adjudication indicator 3 (3 Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Clinical: Society Comment" as the rationale.

Which NDCs map to J2353?

The October 2026 ASP crosswalk lists 9 NDCs from 3 labelers: Sandostatin Lar Depot (Novartis Pharmaceuticals Corporation); Octreotide Acetate (Teva Pharmaceuticals USA, Inc.); Octreotide Acetate (Mylan Institutional LLC). For example NDC 00078-0811-81 is a 1 package equal to 10 billing units. The crosswalk's billing-units-per-package figure converts each package into J2353 units.

Does J2353 have NCCI bundling edits?

No active practitioner PTP pairs list J2353 as a column-1 or column-2 code in the v323r0 release. Unit limits (MUE) and medical-necessity coverage rules still apply.

Which Medicare coverage articles mention J2353?

1 current Billing and Coding Article in the Medicare Coverage Database list J2353, covering 7 states: (Billing and Coding: Octreotide Acetate for Injectable Suspension (Sandostatin® LAR Depot)).

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-10-01. Verify against the primary file before billing or contracting decisions.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B and the Medicare Coverage Database. Payment limits are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.